Cantor Fitzgerald Forecasts Xencor FY2025 Earnings

Key Points

• Cantor Fitzgerald forecasts Xencor's FY2025 earnings per share to be ($2.61), which is an improvement from the consensus estimate of ($3.68) per share.
• The biopharmaceutical company has received mixed ratings from analysts, with Cantor Fitzgerald maintaining an "Overweight" rating and a target price of $40.00, while other analysts have issued lower targets and ratings.
• Xencor reported a quarterly revenue of $43.61 million, significantly surpassing estimates, which indicates strong growth with an 82.4% rise year-over-year.

Xencor, Inc. (NASDAQ:XNCR - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Xencor in a research note issued to investors on Monday, October 6th. Cantor Fitzgerald analyst S. Seedhouse expects that the biopharmaceutical company will earn ($2.61) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $40.00 target price on the stock. The consensus estimate for Xencor's current full-year earnings is ($3.68) per share. Cantor Fitzgerald also issued estimates for Xencor's FY2026 earnings at ($3.55) EPS.

Other equities research analysts also recently issued reports about the company. Barclays started coverage on Xencor in a research report on Wednesday, September 17th. They set an "underweight" rating and a $6.00 price objective on the stock. Royal Bank Of Canada decreased their price target on Xencor from $32.00 to $15.00 and set an "outperform" rating on the stock in a report on Thursday, August 21st. Weiss Ratings reissued a "sell (e+)" rating on shares of Xencor in a research note on Saturday, September 27th. Wedbush reissued an "outperform" rating and issued a $26.00 target price on shares of Xencor in a research note on Tuesday, September 2nd. Finally, Bank of America lowered shares of Xencor from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $23.00 to $12.00 in a research report on Wednesday, September 3rd. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Xencor presently has an average rating of "Moderate Buy" and a consensus price target of $24.22.

Xencor Trading Up 0.2%

Shares of NASDAQ XNCR opened at $11.79 on Tuesday. Xencor has a 12-month low of $6.92 and a 12-month high of $27.24. The firm's 50-day moving average price is $8.86 and its 200-day moving average price is $9.00. The stock has a market capitalization of $840.90 million, a price-to-earnings ratio of -4.91 and a beta of 0.96.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.78) by $0.37. The company had revenue of $43.61 million for the quarter, compared to the consensus estimate of $22.59 million. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. Xencor's revenue was up 82.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.07) earnings per share.

Hedge Funds Weigh In On Xencor

Institutional investors have recently made changes to their positions in the company. Principal Financial Group Inc. increased its position in Xencor by 2.5% during the 1st quarter. Principal Financial Group Inc. now owns 348,726 shares of the biopharmaceutical company's stock valued at $3,710,000 after purchasing an additional 8,581 shares during the period. Invesco Ltd. increased its position in Xencor by 44.3% during the 1st quarter. Invesco Ltd. now owns 656,201 shares of the biopharmaceutical company's stock valued at $6,982,000 after purchasing an additional 201,456 shares during the period. Goldman Sachs Group Inc. increased its holdings in Xencor by 89.9% during the first quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company's stock valued at $7,732,000 after buying an additional 344,088 shares during the period. US Bancorp DE increased its holdings in Xencor by 312.0% during the first quarter. US Bancorp DE now owns 10,432 shares of the biopharmaceutical company's stock valued at $111,000 after buying an additional 7,900 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Xencor during the first quarter valued at approximately $135,000.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.